Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Honey-bee Venom Immunotherapy Failure
NCT02968394Unknown
- Sponsor
- University Clinic of Pulmonary and Allergic Diseases Golnik
- Start
- Mar 2014
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of omalizumab in Hymenoptera venom allergy (HVA), sponsored by University Clinic of Pulmonary and Allergic Diseases Golnik. Primary endpoint: Number of systemic reactions during ultra rush immunotherapy build up phase and maintenance phase at 2 months. Status: unknown.
02
Drugs
omalizumab
03
Conditions
Hymenoptera venom allergy (HVA)
Beyond the preview
Go deeper on NCT02968394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968394.